NASDAQ · ALNY
Alnylam Pharmaceuticals, Inc.
$174.00-$58.40 (-25.13%)
Alnylam Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 63.73% below the high.
Loading market information…
NASDAQ · BBIO · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
BridgeBio Pharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 24.29% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
BridgeBio Pharma, Inc.’s next earnings report is currently expected on Feb 23, 2027, with estimated earnings per share of -$0.53. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow BridgeBio Pharma, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
BridgeBio Pharma, Inc. is a pharmaceutical company dedicated to identifying, advancing, and providing medical solutions for various genetic conditions. The firm boasts an extensive portfolio comprising 30 distinct development initiatives, spanning the entire spectrum from initial discovery research to advanced clinical trial phases. Notable candidates within its development pipeline include: AG10 and BBP-265: A small molecule designed to stabilize transthyretin (TTR), currently in a pivotal Phase 3 clinical trial targeting transthyretin amyloidosis-cardiomyopathy (ATTR-CM). BBP-831: A selective small molecule inhibitor of FGFR1-3, which is undergoing Phase 2 clinical evaluation for treating achondroplasia in pediatric patients. BBP-631: An AAV5 gene transfer product candidate, also in Phase 2 clinical trials, aimed at congenital adrenal hyperplasia (CAH) caused by 21-hydroxylase deficiency (21OHD). Furthermore, BridgeBio is developing: Encaleret: A small molecule antagonist of the calcium sensing receptor (CaSR), presently in a Phase 2 proof-of-concept study for Autosomal Dominant Hypocalcemia Type 1 (ADH1). BBP-711: Intended for the management of hyperoxaluria and individuals prone to recurring kidney stones. Beyond these specific programs, the company is actively engaged in developing therapies for a broader range of Mendelian disorders, oncological diseases, and gene therapy applications. BridgeBio Pharma, Inc. maintains strategic licensing and collaboration agreements with institutions such as Leland Stanford Junior University, The Regents of the University of California, and Leidos Biomedical Research, Inc. Established in 2015, the company's corporate headquarters are situated in Palo Alto, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:24 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q2 2025 | Aug 5, 2025 | -$0.95-14.46% vs estimate | $110.57M+2.26% vs estimate |
|---|
| Q1 2025 | Apr 29, 2025 | -$0.88+12.0% vs estimate | $116.63M+70.48% vs estimate |
|---|
| Q4 2024 | Feb 20, 2025 | -$1.31-20.18% vs estimate | $5.88M+45.62% vs estimate |
|---|
THE ANALYST VIEW
28 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 12 contributors · Median target $110.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$174.00-$58.40 (-25.13%)
Alnylam Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 63.73% below the high.
$253.00+$3.45 (+1.38%)
Ascendis Pharma A/S’s quoted price sits in the upper half of its reported 52-week range, 10.33% below the high.
$57.49+$1.49 (+2.66%)
BioMarin Pharmaceutical Inc.’s quoted price sits in the lower half of its reported 52-week range, 19.01% below the high.
$44.39-$0.51 (-1.14%)
Ionis Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 48.82% below the high.
$44.18+$0.93 (+2.15%)
Scholar Rock Holding Corporation’s quoted price sits in the lower half of its reported 52-week range, 28.47% below the high.
$64.46+$1.44 (+2.28%)
PTC Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 29.06% below the high.
$50.57-$0.28 (-0.54%)
Travere Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 26.42% below the high.
$19.32+$0.03 (+0.16%)
Denali Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 29.23% below the high.
